Press release - 11/06/2025 Antiviral tests on protective clothing for infection control Textiles functionalized with antiviral agents are intended to reduce the risk of transmission of pathogens, particularly in a medical environment. These antiviral properties must be carefully tested and verified in laboratory tests. The biological testing laboratory of the German Institutes of Textile and Fiber Research Denkendorf has examined antiviral activities with coronaviruses as part of a research project on textiles for infection control.https://www.gesundheitsindustrie-bw.de/en/article/press-release/antiviral-tests-protective-clothing-infection-control
Press release - 24/07/2025 What makes cells migrate – and what can stop them Konstanz researchers identify an enzyme that plays a role in the migration of cells in our body - not only during normal tissue formation and wound healing, but also when tumor cells metastasize. This makes the enzyme an interesting candidate for potential future therapeutic approaches.https://www.gesundheitsindustrie-bw.de/en/article/press-release/what-makes-cells-migrate-and-what-can-stop-them
Press release - 04/08/2025 FOXP1 syndrome: Potential therapeutic approach discovered for rare language development disorder FOXP1 syndrome is a congenital disorder in which the brain development of affected children is severely impaired due to a genetic variant. A research team from the Medical Faculty Heidelberg at Heidelberg University has now demonstrated in mice, that the inhibition of a specific enzyme in the brain can improve abnormal behavior and immune cell dysfunction in the brain. The results have been published in the journal Advanced Science.https://www.gesundheitsindustrie-bw.de/en/article/press-release/foxp1-syndrome-potential-therapeutic-approach-discovered-rare-language-development-disorder
Press release - 14/08/2025 Speeding up long-term memory Svenja Brodt uses MRI brain scans to investigate how impressions become memories. A better understanding of how long-term memories are formed could help Alzheimer's patients cope with their daily lives. Impaired memory formation could be compensated for by targeted repetition.https://www.gesundheitsindustrie-bw.de/en/article/press-release/speeding-long-term-memory
Press release - 07/11/2025 How the biological clock ticks in the female reproductive tract - Breakthrough of the Year Award 2025 for Ângela Gonçalves Endometriosis, menopause, ovarian cancer – still poorly researched and often misdiagnosed. Ângela Gonçalves combines AI, molecular biology, and clinical findings to develop non-invasive tools for early detection, personalized care, and healthier aging. The scientist from the DKFZ-Hector Cancer Institute is the winner of the Falling Walls Foundation's “Breakthrough of the Year 2025” award in the Women's Impact category.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-biological-clock-ticks-female-reproductive-tract-breakthrough-year-award-2025-angela-goncalves
Press release - 13/11/2025 New Initiative: Light for Public Health Light affects how we sleep, feel, and perform – yet public awareness of its impact remains limited. The Light for Public Health initiative aims to make evidence-based knowledge on light and health both accessible and actionable, thus turning scientific insight into public benefit.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-initiative-light-public-health
Press release - 26/01/2026 AI learns from animals: New approach to improve surgical imaging Scientists at the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD), and Mannheim University Medical Center (UMM) are presenting a method that enables artificial intelligence (AI) to learn how to transfer medical image data from animals to humans. This “xeno-learning” could help make surgical procedures safer and more precise in the future – without relying on human training data.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-learns-animals-new-approach-improve-surgical-imaging
Press release - 18/02/2026 3D microtumors could revolutionize treatment decisions Chemotherapy is often a central component of treatment for advanced colorectal cancer. However, not every therapy is equally effective for every patient. Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* stem cell institute, and the biotech company Xilis in Utrecht, Netherlands, have now developed a new method for selecting the most effective drug before treatment begins. https://www.gesundheitsindustrie-bw.de/en/article/press-release/3d-microtumors-could-revolutionize-treatment-decisions
Press release - 12/03/2026 Brain Diseases: Certain Neurons Are Especially Susceptible to ALS and FTD Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) belong to a spectrum of neurodegenerative diseases with overlapping symptoms. Many patients have a common hallmark: A protein called TDP-43 clumps together in the neurons of the brain to form tiny lumps. Researchers at DZNE and Ulm University Hospital, together with international experts, have now discovered that these pathological changes primarily affect certain cells. https://www.gesundheitsindustrie-bw.de/en/article/press-release/brain-diseases-certain-neurons-are-especially-susceptible-als-and-ftd
Press release - 03/06/2026 Fat hack protects against cell death In response to stress or damage, cells undergo senescence and stop dividing. However, if senescent cells accumulate in tissues over the long term, chronic inflammation occurs and the risk of cancer increases. Researchers at the German Cancer Research Center (DKFZ) have now discovered a previously unknown mechanism by which senescent cells protect themselves from oxidative stress and a specific form of cell death known as ferroptosis. https://www.gesundheitsindustrie-bw.de/en/article/press-release/fat-hack-protects-against-cell-death
Press release - 06/02/2023 Fewer side effects thanks to personalised medicine Patients have 30 percent fewer serious side effects when medication doses are tailored to their genetic profile. This is what an international research consortium has found out, including the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology at the Bosch Health Campus. With an individual DNA medication pass, as used in the study, treatments can be made more effective and safer in the future.https://www.gesundheitsindustrie-bw.de/en/article/press-release/weniger-nebenwirkungen-dank-personalisierter-medizin
Dossier - 11/10/2023 The quantum revolution in the healthcare industry From ultra-fast quantum computers to highly sensitive sensors - quantum technologies could take medicine a giant step forward. Possible areas of application range from drug development and early cancer detection to reading brain waves to control prostheses or exoskeletons. The German state of Baden-Württemberg plays a key role in the development of sensors in particular.https://www.gesundheitsindustrie-bw.de/en/article/dossier/The-quantum-revolution-in-the-healthcare-industry
Press release - 03/07/2025 Focus on Muscle Metabolism: Sex Differences in Sport and Obesity The skeletal muscles of men and women process glucose and fats in different ways. A study provides the first comprehensive molecular analysis of these differences. The results possibly give an explanation why metabolic diseases such as diabetes manifest differently in women and men – and why they respond differently to physical activity. https://www.gesundheitsindustrie-bw.de/en/article/press-release/focus-muscle-metabolism-sex-differences-sport-and-obesity
Press release - 12/08/2025 Biomarkers for Brain Insulin Resistance Discovered in the Blood If the brain no longer responds properly to insulin (insulin resistance), this can lead to overweight, diabetes, and Alzheimer's disease. Researchers at the DZD in Potsdam and Tübingen have discovered small chemical modifications to genetic material (epigenetic changes*) in the blood that indicate how well the brain responds to insulin. These markers could help to detect insulin resistance in the brain – by means of a simple blood test.https://www.gesundheitsindustrie-bw.de/en/article/press-release/biomarkers-brain-insulin-resistance-discovered-blood
Press release - 09/10/2025 Transparent artificial intelligence improves assessment of prostate cancer aggressiveness Until today, the aggressiveness of prostate cancer has been assessed primarily using the Gleason grading system—an analysis of cancer tissue in a pathology laboratory that is highly subjective. An international research team led by the German Cancer Research Center (DKFZ) has now developed a novel, explainable AI model that aims to make the diagnosis of prostate cancer more transparent and less susceptible to error.https://www.gesundheitsindustrie-bw.de/en/article/press-release/transparent-artificial-intelligence-improves-assessment-prostate-cancer-aggressiveness
Press release - 07/11/2025 Overcoming Tumor Resistance to Immunotherapy: The European Research Council awards international project led by Heidelberg Medical Faculty In the PRECISION-ImmunoRad project, a multidisciplinary team of scientists from Heidelberg, USA, and Cyprus will unite their expertise to develop novel curative therapeutic strategies for currently hard-to-treat cancers. These strategies will integrate high-precision ion beam therapy with genetically engineered immune cells therapies (CAR-T cells), personalized cancer vaccines, and the targeted reprogramming of the tumor immune microenvironment. https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-tumor-resistance-immunotherapy-european-research-council-awards-international-project-led-heidelberg-medical-faculty
Press release - 02/03/2026 Novel therapy for Phelan-McDermid syndrome Drug development to be funded with up to 1.7 million euros An international team led by Professor Tobias M. Böckers from Ulm University Medical Centre has been awarded up to 1.7 million euros to develop a novel therapy for a rare, syndromic form of autism. The research project focuses on a gene whose loss of function can manifest itself in severe impairments in language, behaviour and everyday functions of those affected.https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-therapy-phelan-mcdermid-syndrome-drug-development-be-funded-17-million-euros
Press release - 26/05/2026 Heidelberg based development revolutionizes hepatitis D therapy worldwide: US Food and Drug Administration (FDA) approves hepatitis drug Hepcludex (bulevirtide) Joint press release of the Heidelberg Faculty of Medicine at Heidelberg University and the German Center for Infection Research: With the FDA approval of Hepcludex (bulevirtide), a therapy for chronic hepatitis D developed at the Heidelberg Faculty of Medicine at Heidelberg University, Heidelberg University Hospital, and the German Center for Infection Research (DZIF) has now reached the world’s most important pharmaceutical market.https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-based-development-revolutionizes-hepatitis-d-therapy-worldwide-us-food-and-drug-administration-fda-approves-hepatitis
CeGat GmbH - 06/08/2020 CeGaT: Specific coronavirus antibody test for all Have I perhaps already had COVID-19 in the past? This is a question many of us have been asking. Reliable tests that would provide the answer have simply not been available until now. However, the Tübingen-based biotech company CeGaT is now offering a coronavirus antibody test to anyone who wants one, thus answering this question with the highest probability currently possible. Response to the offer has been huge in the few weeks since the test…https://www.gesundheitsindustrie-bw.de/en/article/news/cegat-specific-coronavirus-antibody-test-all
Article - 04/11/2020 Rapid coronavirus test delivers results in 43 minutes The Hahn-Schickard Institute and Spindiag GmbH in Freiburg im Breisgau have joined forces to develop a rapid test used at the point of care. The test takes just 43 minutes to show whether a patient is infected with the coronavirus SARS-CoV-2. The rapid test is expected to be given market approval in Germany and the EU during the final quarter of 2020.https://www.gesundheitsindustrie-bw.de/en/article/news/rapid-coronavirus-test-delivers-results-43-minutes
Tumour organoids facilitate drug discovery - 20/07/2023 Drug screening for children with cancer using patient-specific miniature tumours Standard drugs often don’t work in children and adolescents with recurrent cancer. Researchers from the Hopp Children's Tumour Centre (KITZ) and the German Cancer Research Center (DKFZ) in Heidelberg have been looking to open up new therapy options for those affected, and have cultivated individual miniature tumours from biopsy samples to test the effectiveness of a variety of drugs within a few weeks.https://www.gesundheitsindustrie-bw.de/en/article/news/drug-screening-children-cancer-using-patient-specific-miniature-tumours
Press release - 23/05/2024 Predicting cancer risks on the basis of national health data Scientists from the German Cancer Research Center (DKFZ) and the European Bioinformatics Institute EMBL-EBI, Hinxton, UK, are using the Danish health registers to predict individual risks for 20 different types of cancer with a high degree of accuracy. The prediction model can also be transferred to other healthcare systems. https://www.gesundheitsindustrie-bw.de/en/article/press-release/predicting-cancer-risks-basis-national-health-data
Press release - 22/08/2024 Validated targets for personalized cancer immunotherapy Knowledge of the target structures for the immune cells is a basic prerequisite for the development of personalized cancer immunotherapies. Scientists from the German Cancer Research Center and the NCT Heidelberg are publishing a sensitive method based on mass spectroscopy to identify such tumor-specific "neoepitopes". The analytical method is designed to detect these low abundance protein fragments and requires minimal amounts of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/validated-targets-personalized-cancer-immunotherapy
Press release - 26/11/2024 Collaborative research centres on kidney and brain prolonged On 25 November, the German Research Foundation (DFG) announced the continued funding of two existing Collaborative Research Centres (CRC) at the University of Freiburg’s Faculty of Medicine. In CRC 1453 Nephrogenetics (NephGen), doctors and researchers are using genetic information to search for mechanisms underlying kidney diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/collaborative-research-centres-kidney-and-brain-prolonged